Could you plz check- what are their plan about new product line(s) e.g. lubricant etc, in terms of revenue share, market share etc. Planning to launch any other new products?- How are they planning to reduce their dependence on FC.

Thanks for the update RJ. Have you initiated any discussion threads for the new opportunities that you are exploring / invested in? I am an admirer of your approach for bottom up stock picking. Would love to learn and contribute towards new ideas that you are considering. If it's too early for you to discuss about any of them then I totally understand.

@rathiraunak71 thanks. please check on following:1. Any major order book opportunity coming in next 3-6 months from any existing/new client?2. B2C adoption of FC - any learning since as per few doctors, using is a cumbersome process and hence adaptability3. Any new insights on change in management structure, new leadership hiring etc

As per last concall, the USFDA approvals would need upto 15/20cr. Clinical trials itself cost 2 mil. This would be needed over the period of 2 yrs. My guess is that the additional money would be for acquisition. Let’s hear that from management during concall whenever it gets scheduled. I do have following additional questions, putting it across so that we can collaborate and ask questions whoever gets opportunity during con call. 1. What do we plan to do with additional capital being raised? 2…

There are several interesting aspects to the announcement. 1. I am seeing name of Mr. Durgesh Garg -COO for the first time (he has signed the letter written to BSE/NSE) It means their company secretary has left the company or Durgesh getting more powerful in the organisation.2. Mr. Om Garg was talking for last 6 months about hiring a CEO and now he has hired Chief BDO. Does this mean plan for CEO hiring is postponed/cancelled or does it mean COO will be next in line to become CEO3. Recent share transfers from Mr. Om Garg to his wife and this announcement has any connection? Is Mr. Garg stepping out?

I may be reading too much into it but it pays to be skeptical in case of small companies like Cupid

Very nice to hear from Mr. Garg. He mentioned FY17 sales of Rs84-85crs. Looks like company can deliver EPS of Rs18 to Rs19 in FY17. Management highlighted that they are looking at hand sanitizers, sanitary napkins, baby diapers and vaginal creams as new product lines. Also applying for FDA approval. Also expanding capacity for male and female condoms and lubricants.

ELARA INDIA OPPORTUNITIES FUND LIMITED could have bought the shares from the open market. I'm not sure why the promotors of the company transferred and sold some shares. Maybe Mr. Garg is not very confident with the company or maybe something else. However I feel that taking such risks in this small cap company is not worth it.

You should see the video which shared some comments above...else Mr garg didn't tell about transfer of share but he telling the future path of cupid ltd. cupid is very good bet for longterm and cupid's management is very transparent towards their shareholders.

The expansion plans doesn't look impressive. All these categories are commodity grade with entrenched players. Do they want to become contract manufacturers? Secondly, raising fund for these expansions is not a great move. I would have been ok if they used their FCF for the same. All these categories will require brand building etc while they have not been a great success so far in their core competence of FCs.

lots of cupid investors have become jittery lately because of all the unknown variables surrounding the promoters actions. Good bad i don't know. Sometimes when hard facts are not known it helps to look at what prices are doing before taking a call and the news unfortunately is not encouraging on that front ( at least in the near term ). Have a look at the chart and my reading tells me that the nice little 60 day uptrend has been broken badly.

Fixation on prices is anathema to value investors i know, but if you look at the seasoned value practitioners ( Mohnish Pabrai for example), prices and value are joined at the hip. There IS going to be short term ( i hope it remains short term only ) pain.

But, now is the time to understand and revisit your thesis. To focus on the reason you invested in the company in the first place. If your confidence is going to weaken as the prices go down then its best to move on.

I think that the company is well poised to brand its offerings and pioneer the concept of female condoms in India under the Cupid name. Just get hold of a young popular female celebrity and make the use of FC's cool . That will send the business into a different orbit and start an exciting new story with strong legs to run

For those who think that the business is going to do well in the future lower prices is a cause for celebration and averaging down would be a rational move. I dont see a marketing focus currently so i would wait for a decisive announcement on that front. Till such time it remains on the radar

Just get hold of a young popular female celebrity and make the use of FC's cool . That will send the business into a different orbit and start an exciting new story with strong legs to run

I respect your analytical skills as you have demonstrated in other threads, but I think there are facets to FCs that make their marketing and use a little more nuanced than just slapping a pretty face and putting out ads in the media. You can disagree with me, but you may still want to avoid making such simplistic conclusions as the recipe for success.